<DOC>
	<DOC>NCT01285466</DOC>
	<brief_summary>The purpose of the trial is to determine the maximum tolerated dose (MTD) of BEZ235 and BKM120 in combination with weekly paclitaxel and weekly paclitaxel/trastuzumab.</brief_summary>
	<brief_title>A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patients with metastatic or locally advanced solid tumors, for whom weekly paclitaxel treatment is indicated (BEZ235paclitaxel /BKM120paclitaxel treatment) HER2+ metastatic or locally advanced breast cancer patients eligible for weekly paclitaxel and trastuzumab (BEZ235paclitaxeltrastuzumab /BKM120paclitaxeltrastuzumab treatment) Adult patients (≥ 18 years) (males, females) World Health Organization (WHO) performance status ≤ 2 Adequate bone marrow function: Adequate hepatic and renal function: Patients with primary central nervous system (CNS) tumor or CNS tumor involvement. However, patients with a metastatic CNS lesion may participate in this trial, if the patient is &gt; 4 weeks from therapy (including radiation and/or surgery) completion, clinically stable with respect to the tumor at the time of study entry, and not receiving enzymeinducing antiepileptic drugs or corticosteroid therapy or taper, as treatment of the brain metastases Patients who have received prior systemic anticancer therapy within the following time frames Cyclical chemotherapy: ≤ 3 weeks before study treatment (6 weeks for patients treated with nitrosoureas) Biological therapy: ≤ 4 weeks before study treatment, except treatment with trastuzumab (both parts of the trial) Investigational drug: ≤ 4 weeks before study treatment Patients who have undergone major surgery ≤ 4 weeks before study treatment Patients receiving chronic treatment with corticosteroids or other immunosuppressive agents Patients with uncontrolled, unmanageable, treatmentrefractory diabetes mellitus Active or history of major depressive episode, bipolar disorder, obsessivecompulsive disorder, schizophrenia, history of suicide attempt or ideation, or homicide, as judged by the investigator and/or based on recent psychiatric assessment Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>BEZ235</keyword>
	<keyword>BKM120</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>trastuzumab</keyword>
</DOC>